TherapeuticsMD Q1 Net Income of $103 Thousand; License Revenue Rises to $724 Thousand
TherapeuticsMD reported net income from continuing operations of $103 thousand for the quarter ended March 31, 2026, compared with a net loss of $636 thousand a year earlier. License revenue rose to $724 thousand, mainly from the Mayne License Agreement, while operating expenses fell 13.6%. The company also said it is still exploring strategic alternatives, including a possible acquisition, merger, or sale of assets, with no timetable set.
Key points
- Net income from continuing operations was $103 thousand, versus a net loss of $636 thousand in Q1 2025.
- License revenue was $724 thousand, up $331 thousand from $393 thousand in Q1 2025.
- Total operating expenses were $1,447 thousand, down $227 thousand or 13.6% from $1,674 thousand.
- Cash and cash equivalents totaled $8.4 million as of March 31, 2026; the strategic review has no set timetable.
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 12, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.